Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.

Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.

The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.

Servier's vorasidenib had shown promise at ASCO, but Lilly's dual IDH project LY3410738 leaves the pipeline.